Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. … Read more
Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) - Total Assets
Latest total assets as of September 2025: ₹2.99 Billion INR
Based on the latest financial reports, Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) holds total assets worth ₹2.99 Billion INR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Jagsonpal Pharmaceuticals Limited - Total Assets Trend (2006–2025)
This chart illustrates how Jagsonpal Pharmaceuticals Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Jagsonpal Pharmaceuticals Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Jagsonpal Pharmaceuticals Limited's total assets of ₹2.99 Billion consist of 57.9% current assets and 42.1% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 46.3% |
| Accounts Receivable | ₹131.76 Million | 4.7% |
| Inventory | ₹152.00 Million | 5.5% |
| Property, Plant & Equipment | ₹847.61 Million | 30.5% |
| Intangible Assets | ₹759.24 Million | 27.3% |
| Goodwill | ₹96.93 Million | 3.5% |
Asset Composition Trend (2006–2025)
This chart illustrates how Jagsonpal Pharmaceuticals Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jagsonpal Pharmaceuticals Limited's current assets represent 57.9% of total assets in 2025, a decrease from 74.1% in 2006.
- Cash Position: Cash and equivalents constituted 46.3% of total assets in 2025, up from 2.8% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 30.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is property, plant & equipment at 30.5% of total assets.
Jagsonpal Pharmaceuticals Limited Competitors by Total Assets
Key competitors of Jagsonpal Pharmaceuticals Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Jagsonpal Pharmaceuticals Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Jagsonpal Pharmaceuticals Limited generates 0.97x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Jagsonpal Pharmaceuticals Limited generates $ 19.90 in net profit.
Jagsonpal Pharmaceuticals Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.07 | 2.95 | 2.60 |
| Quick Ratio | 5.59 | 2.60 | 2.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₹1.69 Billion | ₹ 917.95 Million | ₹ 682.07 Million |
Jagsonpal Pharmaceuticals Limited - Advanced Valuation Insights
This section examines the relationship between Jagsonpal Pharmaceuticals Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.84 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 28.2% |
| Total Assets | ₹2.78 Billion |
| Market Capitalization | $34.15 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jagsonpal Pharmaceuticals Limited's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Jagsonpal Pharmaceuticals Limited's assets grew by 28.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Jagsonpal Pharmaceuticals Limited (2006–2025)
The table below shows the annual total assets of Jagsonpal Pharmaceuticals Limited from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹2.78 Billion | +28.18% |
| 2024-03-31 | ₹2.17 Billion | +11.35% |
| 2023-03-31 | ₹1.95 Billion | +15.73% |
| 2022-03-31 | ₹1.68 Billion | +2.59% |
| 2021-03-31 | ₹1.64 Billion | +11.74% |
| 2020-03-31 | ₹1.47 Billion | +8.23% |
| 2019-03-31 | ₹1.36 Billion | +4.60% |
| 2018-03-31 | ₹1.30 Billion | -8.97% |
| 2017-03-31 | ₹1.43 Billion | -10.47% |
| 2016-03-31 | ₹1.59 Billion | +3.28% |
| 2015-03-31 | ₹1.54 Billion | -1.30% |
| 2014-03-31 | ₹1.56 Billion | +2.13% |
| 2013-03-31 | ₹1.53 Billion | -1.98% |
| 2012-03-31 | ₹1.56 Billion | +14.18% |
| 2011-03-31 | ₹1.37 Billion | +10.94% |
| 2010-03-31 | ₹1.23 Billion | +0.38% |
| 2009-03-31 | ₹1.23 Billion | -5.74% |
| 2008-03-31 | ₹1.30 Billion | -11.68% |
| 2007-03-31 | ₹1.47 Billion | +4.19% |
| 2006-03-31 | ₹1.42 Billion | -- |